Observational studyBMC infectious diseases2026
Vaccine-preventable viral hepatitis in men living with HIV/AIDS - immunity and associated factors.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeople living with HIV/AIDS (PLWHA) have a higher risk of morbidity and mortality from acquiring infectious diseases, including those preventable by vaccination, such as hepatitis A and B. This study aimed to analyze the immunity of men living with HIV to hepatitis A and B, with emphasis on those in the MSM category, to identify the factors associated with this immunity.
methodsThis is a retrospective, analytical, observational study of cases of men living with HIV, as reported in the Notifiable Diseases Information System of the municipality of Ribeirão Preto, São Paulo, Brazil, between 2015 and 2020. Data were collected from different information systems in 2021 and 2022 using a REDCap platform form. Sociodemographic, clinical and vaccine-related data were collected. Descriptive analysis, assessment of associations, and logistic regression were performed.
resultsThe sample consisted of 538 men living with HIV, 55% of whom were immune to hepatitis B, with the highest proportion of reactive anti-HBs in the first collection of this test in the 20-29 age group (67.8%). Men living with HIV/AIDS with adequate vaccination status were 5.6 times more likely to have reactive anti-HBs (aOR: 5.65, 95% CI: 3.04-10.51; p = 0.000). In the assessment of immunity to hepatitis A, the highest proportions of individuals with non-reactive anti-HAV IgG were in the 13-19 year age group (20; 76.9%; p = < 0.001). In the multivariate analysis, men living with HIV/AIDS aged 40 and over were 19.6 times more likely (aOR: 19.68, 95% CI: 4.61-83.94; p = 0.000) to be immune to hepatitis A compared to men living with HIV/AIDS aged 13-19.
conclusionsOur findings reinforce the importance of serological screening and ensuring the completion of vaccination schedules in all PLWHA, especially among those who are not immune.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.